EUCTR2012-004470-25-GB进行中（未招募）不适用
A multicentre, randomised, double-blind, two arm, parallel group, pilot study to assess the effect of Gaviscon® Double Action Mint as add-on therapy in GORD patients with inadequate response to once daily proton pump inhibitor treatment. - Gaviscon® Double Action Mint as add-on therapy in GORD patients with inadequate response to PPI's
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Informed consent has been obtained.
- •2.Age: = 18 years.
- •3.Sex: male or female.
- •4.Current evidence of symptomatic GORD in accord with the Montreal definition following treatment with a proton pump inhibitor. This evidence can be based solely on symptom characteristics.
- •5.Patients must have had troublesome heartburn or regurgitation of at least mild or moderate intensity* on at least three days a week during the two weeks before the start of screening. If the patient also has other symptoms, the heartburn or regurgitation must be the predominant symptoms.
- •*Symptom intensity should be assessed using the following scale;
- •Mild: awareness of symptom but easily tolerated
- •Moderate: discomforting symptom sufficient to cause interference with normal activities including sleep
- •Severe: incapacitating symptom with inability to perform normal activities, including sleep
- •6.Treatment with once daily PPI for at least the previous 4 weeks at standard doses, eg, lansoprazole 30 mg per day, omeprazole 10 to 40 mg per day, pantoprazole 20 to 40 mg per day.
- •7.Compliance regarding use of prescribed once-daily PPI over 4 weeks, as determined by the investigator.
- •8.Status: subjects will be members of the public who respond to an advertisement or letter from the site.
- •Following the 7-day run in period, patients will be assessed against the following inclusion criteria before randomisation.
- •1.Completion of the run-in diary card and questionnaires on each of the seven days of the run-in period.
- •2.At least one reflux symptom (heartburn or regurgitation) of at least mild or moderate intensity measured during the 7-day run-in period (from the HRDQ questionnaire) and a summarised 7-day score of at least 18 (e.g. corresponding to 3 days with moderate heartburn on three occasions per day). (The daily score will be calculated as intensity x frequency, where intensity is scored as 0 = none, 1 = mild, 2 = moderate and 3 = severe and frequency is scored as 0 = none, 1 = once, 2 = twice, 3 = thrice, 4 = 4 or 5 times, 5 = 6 – 10 times and 6 = more than 10 times or constant).
- •3.Compliance with PPI treatment (once daily in the morning) on all seven days of the run-in period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1.Oesophageal stricture (diagnostically confirmed), peptic ulcer disease, Zollinger-Ellison syndrome, systemic sclerosis, hiatus hernia (diagnostically confirmed), recent (with last year) upper gastrointestinal endoscopy examination that has shown LA grade C or D oesophagitis.
- •2.A recent history of drug, solvent or alcohol abuse (weekly alcohol intake = 140g or 17.5 units).
- •3.Recent cardiac chest pain.
- •4.Recent, significant unexplained weight loss of greater than 6 kg in the last 6 months.
- •5.Gastro-intestinal bleeding (hematochezia or hematemesis) within the last 3 months.
- •6.Non-steroidal anti-inflammatory drugs or other analgesics in doses that might compromise symptom recording.
- •7. Patients who have taken any of the following treatments in the week prior to the screening visit (Visit 1) and who may require any of these during the study (as they are also excluded throughout the study):
- •H2-receptor antagonists
- •Mucous membrane protection drugs
- •Anti-cholinesterase drugs, sucralfate or misoprostol preparations
- •Antacids (including Gaviscon)
- •8.Current enrolment in another study or involvement in a previous symptom relief Gaviscon study in the past year.
- •9.Previous surgery of the oesophagus, stomach or duodenum.
- •10.Potential language problems in understanding information and recording symptoms.
- •11.Any co-existing condition which, in the opinion of the investigator, would be likely to compromise patient safety or interfere with the assessment of efficacy.
- •12.Female subjects of childbearing potential who, for the duration of the study, are either unwilling or unable to take adequate contraceptive precautions or are unwilling to be sexually abstinent (as defined in Section 10.44).
- •13.Pregnancy or lactating mother.
- •14.Subjects with known hypophosphataemia, phenylketonuria or hypercalcaemia
- •15.Subjects with severe/impaired renal function or insufficiency
- •16.Any previous history of allergy or known intolerance to any of the Investigational medicinal product’s (IMP) or following formulation constituents: e.g. sodium alginate, parabens (methyl and propyl), glucose syrup, carbomer and xanthan gum.
- •17.Previously randomised into the study.
- •18.Employee at study site.
- •19.Partner or first-degree relative of the Investigator.
- •20.Participation in a clinical study in the previous 3 months
- •21.Unable in the opinion of the Investigator to comply fully with the study requirements.
研究者
相似试验
进行中（未招募）
不适用
Study to assess the effect of Gaviscon Advance as add-on therapy in GORD patients with inadequate response to once daily proton pump inhibitor treatment.Gastro Oesophageal Reflux Disease (GORD)MedDRA version: 17.1Level: LLTClassification code 10066874Term: Gastroesophageal reflux diseaseSystem Organ Class: 100000004856EUCTR2011-005486-21-DEReckitt Benckiser Healthcare (UK) Ltd.150
进行中（未招募）
1 期
Study to assess the effect of Gaviscon Advance as add-on therapy in GORD patients with inadequate response to once daily proton pump inhibitor treatment.Gastro Oesophageal Reflux Disease (GORD)MedDRA version: 15.1Level: LLTClassification code 10066874Term: Gastroesophageal reflux diseaseSystem Organ Class: 100000004856EUCTR2011-005486-21-DKReckitt Benckiser Healthcare (UK) Ltd.150
进行中（未招募）
1 期
Sodium alginate liquid suspension as add-on therapy in GORD patients with inadequate response to PPI treatment – a pivotal study.EUCTR2014-003174-17-GBReckitt Benckiser Healthcare (UK) Limited396
进行中（未招募）
1 期
Sodium Alginate Chewable Tablet European Symptom Relief Study for patients with symptoms of GORDEUCTR2014-005261-69-DEReckitt Benckiser Healthcare (UK) Limited493
进行中（未招募）
1 期
Sodium Alginate Chewable Tablet European Symptom Relief Study for patients with symptoms of GORDEUCTR2014-005261-69-GBReckitt Benckiser Healthcare (UK) Limited424